Filing summary
Entity and period: The supplied filing is Torchmark Corporation’s unaudited Form 10-Q for the quarter ended March 31, 2016. This does not match the request metadata naming Globe Life Inc.; verify the issuer before relying on this summary.
Financial results and position
- Revenue: Total revenue was $977.6 million, up 4.6% from $934.4 million. Premium income increased 5.1% to $779.9 million; life premiums rose 6.0% and health premiums 3.1%. Net investment income increased 2.8% to $197.1 million.
- Earnings: Income from continuing operations was $133.6 million, up from $130.8 million. Net income, including a $9.5 million after-tax loss from discontinued operations, was $124.0 million versus $121.6 million. Diluted EPS was $1.01, compared with $0.95; continuing-operations diluted EPS was $1.08 versus $1.02.
- Underwriting: Life underwriting income rose to $144.3 million, but margin declined to 27% from 28%. Health underwriting income was essentially flat at $51.5 million, with margin down to 22% from 23%. Management attributed pressure to higher life policy obligations and health acquisition costs.
- Cash flow: Cash provided by operations was $337.7 million, up from $279.7 million. Investing activities used $332.0 million and financing activities used $48.6 million. Cash ended the quarter at $12.8 million; cash plus short-term investments was $157 million.
- Debt and liquidity: At quarter-end, short-term debt was $557.2 million and long-term debt was $744.0 million. Commercial paper outstanding was $307.6 million, with $265.4 million available under the credit line after letters of credit. On April 5, 2016, after quarter-end, Torchmark issued $300 million of 6.125% subordinated debentures, receiving $290 million net, intending to repay $250 million of 6.375% senior notes due June 2016 and use the balance for general corporate purposes.
- Capital and investments: Shareholders’ equity was $4.39 billion, up from $4.06 billion at year-end, primarily reflecting $303.5 million of other comprehensive income and quarterly net income, partly offset by share repurchases. The fixed-maturity portfolio’s net unrealized gain rose to approximately $970 million from $506 million, principally because Treasury rates declined. About 94% of fixed maturities at amortized cost were investment grade.
Changes, outlook, and notable items
- Total net sales were flat at $136 million; first-year collected premium rose to $113 million from $110 million. Life net sales were flat, while health net sales declined 1% and health first-year collected premium fell 7%.
- Management reported no formal earnings guidance. It expected to sell the Medicare Part D business during 2016, citing declining margins, higher drug and administrative costs, and increased risks; the business was reported as discontinued operations. Its quarterly after-tax loss was $9.5 million, compared with $9.1 million a year earlier.
- Management said Medicare Part D reimbursement and drug-rebate timing reduced first-quarter investment income by approximately $3 million and expected a further approximately $6 million reduction for the remainder of 2016.
- Share repurchases totaled $85.1 million, including purchases funded with excess cash flow and option proceeds; dividends declared were $0.14 per share. Management described continued investment in information technology, contributing to higher administrative expense.
- Early adoption of ASU 2016-09 increased first-quarter 2016 EPS by $0.01 and changed the presentation of excess tax benefits. Management cautioned that future share-price movements and option exercises may increase earnings and EPS volatility.
- Key risks cited include mortality and morbidity differing from assumptions, regulatory and Medicare changes, interest-rate and credit-market movements, pricing competition, litigation, and delays in obtaining health-insurance rate increases. The company reported state unclaimed-property audits for which it could not estimate a potential loss range; management said pending litigation was not expected to have a material adverse effect, while acknowledging punitive-damage uncertainty.
Most important facts for investors to verify
- Confirm that Torchmark Corporation, rather than Globe Life Inc., is the intended filing issuer.
- Track the Medicare Part D sale timing and proceeds, and whether reimbursement delays and discontinued-operation losses change.
- Assess whether elevated Globe Life Direct Response policy obligations persist and whether life and health underwriting margins recover.
- Review energy-sector credit quality, below-investment-grade holdings, unrealized portfolio gains, and the effect of interest-rate changes.
- Confirm the use of proceeds from the April 2016 debt issuance, refinancing of the June 2016 notes, and ongoing liquidity and capital adequacy.